RxDoctor Payments Data

Megan Nugent

Family · Camden, NJNPI 1447843990

Payments from drug & device makers

$298in general payments, 2019–2025

Across 12 payments — averaging $24.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Braeburn Inc.$136
  • AstraZeneca$35
  • Kowa Pharmaceuticals America, Inc.$33
  • Indivior Inc.$30
  • Amgen$28
  • Alkermes, Inc.$18
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$298100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$298 in reported general payments places this provider in the 50th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$86,674
Medicare patients
130
Services billed
824

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban110$97,937
XareltoRivaroxaban25$19,059
JanuviaSitagliptin Phosphate18$17,080
FarxigaDapagliflozin Propanediol18$14,022
TradjentaLinagliptin13$9,720
MyrbetriqMirabegron15$7,158
Atorvastatin Calcium303$4,195
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$3,513
Midodrine Hcl24$2,820
Methenamine Hippurate31$2,802
Potassium Chloride84$2,433
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$2,247
Levothyroxine Sodium202$2,159
Albuterol Sulfate HfaAlbuterol Sulfate54$2,121
Amlodipine Besylate164$2,082

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$35$14,02218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,692 family providers in New Jersey.

Other family in Camden

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →